by David Sires | Jul 17, 2026 | Blog
A new UC San Diego-led study titled “GLP-1 Shows Promise for Patients with Advanced Fatty Liver Disease” provides encouraging evidence that GLP-1 receptor agonists may benefit patients with advanced metabolic dysfunction–associated steatohepatitis (MASH),...
by David Sires | Jul 13, 2026 | Blog
Give this article a read: “Chronic Liver Disease: How PCPs Can Improve Early Detection.” This HCPLive interview with Stevan Gonzalez, MD, MS (Director of Liver Transplantation at Baylor Scott & White Health) is less of a research paper and more of a...
by David Sires | Jul 7, 2026 | Blog
The LinkedIn article titled “Trinity Health Aims to Improve Liver Cancer Screening Rates Through Physician, Patient Education Intervention” highlights a small but potentially high-impact initiative by Trinity Health West Michigan to improve hepatocellular...
by David Sires | Jul 1, 2026 | Blog
The PharmaVoice article titled “3 late-stage MASH drugs that could rival Rezdiffra” highlights the next wave of MASH therapies expected to compete with Madrigal’s Rezdiffra (resmetirom), emphasizing that the future of MASH treatment will likely...
by David Sires | Jun 25, 2026 | Blog
This LinkedIn post highlights a major milestone by the Beth Israel Deaconess Medical Center (BIDMC) Transplant Institute.”The robotic approach brought a new dimension to an already complex operation led by transplant surgeons Drs. Martin Dib and Vincenzo Villani...
